Tags

Type your tag names separated by a space and hit enter

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
Mov Disord 2005; 20(2):151-7MD

Abstract

Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single-dose dopaminergic challenges. Twelve PD patients with on-off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean L-dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The L-dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self-assessment scores reflected these significant changes. Dyskinesia improvement correlated with reduction in oral medication and with the final apomorphine dose (P < 0.05). This prospective study confirms marked dyskinesia reduction on continuous subcutaneous apomorphine therapy, paralleled by reduced dyskinesias during dopaminergic challenge tests. Our findings support the concept that replacement of short-acting oral antiparkinsonian medication with continuous dopamine receptor stimulation may reverse, at least partially, the sensitization process believed to mediate the development of drug-induced dyskinesias in PD.

Authors+Show Affiliations

Reta Lila Weston Institute of Neurological Studies, University College London, United Kingdom.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article

Language

eng

PubMed ID

15390035

Citation

Katzenschlager, Regina, et al. "Continuous Subcutaneous Apomorphine Therapy Improves Dyskinesias in Parkinson's Disease: a Prospective Study Using Single-dose Challenges." Movement Disorders : Official Journal of the Movement Disorder Society, vol. 20, no. 2, 2005, pp. 151-7.
Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. 2005;20(2):151-7.
Katzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., ... Lees, A. J. (2005). Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Movement Disorders : Official Journal of the Movement Disorder Society, 20(2), pp. 151-7.
Katzenschlager R, et al. Continuous Subcutaneous Apomorphine Therapy Improves Dyskinesias in Parkinson's Disease: a Prospective Study Using Single-dose Challenges. Mov Disord. 2005;20(2):151-7. PubMed PMID: 15390035.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. AU - Katzenschlager,Regina, AU - Hughes,Andrew, AU - Evans,Andrew, AU - Manson,Alice J, AU - Hoffman,Marion, AU - Swinn,Lesley, AU - Watt,Hilary, AU - Bhatia,Kailash, AU - Quinn,Niall, AU - Lees,Andrew J, PY - 2004/9/25/pubmed PY - 2005/4/26/medline PY - 2004/9/25/entrez SP - 151 EP - 7 JF - Movement disorders : official journal of the Movement Disorder Society JO - Mov. Disord. VL - 20 IS - 2 N2 - Continuous subcutaneous (SC) infusion of the dopamine agonist apomorphine was shown in retrospective studies to improve drug-induced dyskinesias in Parkinson's disease (PD). We prospectively assessed the antidyskinetic effect of continuous SC apomorphine therapy using subjective and objective measures, and sought to determine whether any observed dyskinesia reduction could be corroborated using single-dose dopaminergic challenges. Twelve PD patients with on-off fluctuations and disabling dyskinesias who were scheduled to start apomorphine pump treatment underwent acute levodopa and apomorphine challenges at baseline and 6 months later. Video recordings involving motor tasks were rated blindly by two independent raters using modified AIMS and Goetz dyskinesia scales. At 6 months, mean apomorphine dose was 75.2 mg per day and the mean L-dopa dose had been reduced by 55%. Daily off time in patients' diaries was reduced by 38% (2.4 hours). The L-dopa challenges showed a reduction of 44% in AIMS and 40% in Goetz scores (both P < 0.01). Apomorphine challenges showed a reduction of 39% in AIMS and 36% in Goetz scores (both P < 0.01). Patients' self-assessment scores reflected these significant changes. Dyskinesia improvement correlated with reduction in oral medication and with the final apomorphine dose (P < 0.05). This prospective study confirms marked dyskinesia reduction on continuous subcutaneous apomorphine therapy, paralleled by reduced dyskinesias during dopaminergic challenge tests. Our findings support the concept that replacement of short-acting oral antiparkinsonian medication with continuous dopamine receptor stimulation may reverse, at least partially, the sensitization process believed to mediate the development of drug-induced dyskinesias in PD. SN - 0885-3185 UR - https://www.unboundmedicine.com/medline/citation/15390035/Continuous_subcutaneous_apomorphine_therapy_improves_dyskinesias_in_Parkinson's_disease:_a_prospective_study_using_single_dose_challenges_ L2 - https://doi.org/10.1002/mds.20276 DB - PRIME DP - Unbound Medicine ER -